Skip to content
2000
Volume 6, Issue 1
  • ISSN: 1574-891X
  • E-ISSN: 2212-4071

Abstract

Although carbapenem antibiotics are one of the most effective agents in the treatment of nosocomial infections caused by Gram-negative bacteria, their use is threatened by the emergence of antibiotic resistance. The bacterial resistance to carbapenems parallels their increasing use and has dramatic clinical implications such as increase in mortality and cost of care. This article reviews recently published patents claiming for carbapenem antibacterial agents. New forms including crystalline forms with high oral bioavailability and modified spectrum including methicillinresistant Staphylococci are some of new patents described in this review.

Loading

Article metrics loading...

/content/journals/pri/10.2174/157489111794407886
2011-01-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/pri/10.2174/157489111794407886
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test